[Surveillance of susceptibility of clinical isolates to cefmetazole between 2000 and 2002].

The antibacterial activity of cefmetazole (CMZ) against clinical isolates from 15 medical institutions all over Japan was evaluated yearly for two years from June 2000 to March 2002 and compared with that of other parenteral beta-lactams, cefazolin (CEZ), cefotiam (CTM), sulbactam/cefoperazone (SBT/CPZ), and flomoxef (FMOX). In the first surveillance from June 2000 to March 2001, 575 isolates of 13 species were tested, and 548 isolates of the same 13 species were tested in the second surveillance from April 2001 to March 2002. In these surveillances spanning two years, the MIC90s of CMZ against the bacterial species tested hardly differed.

[Antibacterial activity of cefpodoxime against clinical isolates in 2000 and 2001].

As the post-marketing surveillance of cefpodoxime proxetil (Banan), MICs of cefpodoxime (CPDX, an active form of Banan) against 1090 clinical isolates of 22 species from 15 medical institutions all over Japan from June 2000 to March 2001 were measured using the broth microdilution method approved by the Japanese Society of Chemotherapy and compared with those of oral cephem antibacterials, cefaclor, cefdinir, cefditoren, and cefcapene. In this study, remarkable change in the activity of CPDX was observed in Streptococcus pneumoniae and Haemophilus influenzae compared with the susceptibility in the studies before Banan was launched. This cause is considered to be the increase in the incidence of the following resistant strains: penicillin-intermediate S.

[Antibacterial activity of panipenem against clinical isolates in 2000 and 2001].

As the post-marketing surveillance of panipenem/betamipron (Carbenin), MICs of panipenem (PAPM) against 1355 clinical isolates of 28 species from 15 medical institutions all over Japan from June 2000 to March 2001 were measured using the broth microdilution method approved by the Japanese Society of Chemotherapy and compared with those of parenteral carbapenem antibacterials, imipenem (IPM) and meropenem (MEPM), and parenteral cephem antibacterials, cefozopran, cefepime, and sulbactam/cefoperazone. The activity of PAPM was comparable to that of IPM against almost all species tested. Compared with MEPM, PAPM was more active against Gram-positive bacteria and Bacteroides spp.